Akseli Hemminki

Akseli Hemminki is the founder and CEO of TILT Biotherapeutics and the chairman of the board. Akseli has over 10 years of experience in the field of oncology and has worked with some of the leading companies in the field. Akseli has a passion for helping others and has been instrumental in the development of new treatments for cancer patients. Akseli is a respected scientist and doctor, and their work has helped countless people.

Akseli Hemminki is an eMBA from Aalto University Executive Education Ltd, a Research Professor from University of Helsinki, a Specialist in Oncology and Radiotherapy from Helsinki University Central Hospital, and a Docent of Cancer Biology from University of Helsinki. Akseli has also been a Post-doctoral researcher in Gene/Genetic Therapy from University of Alabama at Birmingham, and holds a Doctor of Medicine (M.D.) and a Doctor of Philosophy - PhD in Cancer genetics from University of Helsinki.

Some direct reports include Aino Kalervo - Chief Business Officer, Riikka Kalliokoski - Bachelor of Social and Health Care, Lab Manager, and Claudia Kistler - Head of Clinical Operations.